


PGx



VeriDose® DPYD Panel



Characterize *DPYD* Variants of Interest

Partial or complete lack of dihydropyrimidine dehydrogenase (DPD) enzyme functionality can increase the risk of severe fluoropyrimidine drug toxicity¹. Understanding *DPYD* gene status and its impact on drug metabolism is a rapidly growing focus area in PGx research.

The VeriDose® *DPYD* Panel targets a set of 9 *DPYD* variants associated with an increased risk of severe toxicity, including key variants recommended by leading PGx agencies and consortia.^{2,3}

The Agena Bioscience® Solution

- Single-well multiplex panel for the detection of 9 SNP genotypes associated with increased risk of toxicity
- Use as a stand-alone or in combination with other PGx panels on the same run, creating workflow efficiencies
- Cost-effective analysis with minimal waste

For Research Use Only.
Not for use in diagnostic procedures.

Agena®
BIOSCIENCE

ASSAY COMPONENTS

rsID	Nucleotide Change	Allelic Variant
rs3918290	c.1905+1G>A	DPYD*2A
rs55886062	c.1679T>G	DPYD*13, p.I560S
rs67376798	c.2846A>T	p.D949V
rs75017182	c.1129-5923C>G	HapB3
rs115232898	c.557A>G	p.Y186C
rs56038477	c.1236G>A	E412E
rs115349832	c.959-51T>C	
rs6668296	c.680+139G>A	
rs56276561	c.483+18G>A	

ORDERING INFORMATION

The assay panel sets are available in both 96 and 384 reaction formats to support varying sample throughput.

Catalog No.	Item	# Samples	Format
13330F	VeriDose DPYD Panel Set – CPM (10x96)	960	96 CPM
13331D	VeriDose DPYD Panel Set - CPM (10x384)	3840	384 CPM

References

- <https://doi.org/10.1159/000510258>
- <https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine>
- <https://doi.org/10.1002/cpt.911>

For Research Use Only. Not for use in diagnostic procedures.

Agena Bioscience, Inc.
4755 Eastgate Mall
San Diego, CA 92121
Phone: +1.877.443.6663

Orders: orderdesk@agenabio.com
Website: www.agenabio.com
Support: <https://support.agenabio.com>

